Australia is closely awaiting the arrival of retatrutide, a novel dual GIP and GLP-1 receptor agonist that's generating significant buzz in the global weight management landscape. Developed by Novo Nordisk, this https://caravscy924677.corpfinwiki.com/10057437/novo_nordisk_s_retatrutide_australia_a_potential_hope_for_weight_management